Full-Time

Sr. Director/Executive Director MD

Immunology Clinical Development

Updated on 12/21/2024

Neurocrine Biosciences

Neurocrine Biosciences

1,001-5,000 employees

Healthcare

Compensation Overview

$314k - $454.6kAnnually

+ Bonus + Equity Incentive Program

Senior, Expert

San Diego, CA, USA

Category
Physicians & Surgeons
Medical, Clinical & Veterinary
Requirements
  • MD or DO required
  • At least 6+ years of experience in clinical research and development (Phase I-IV) in immunological or autoimmune disorders in either a pharmaceutical/biotechnology company or a clinical research/academic environment or related experience required
  • Extensive previous leadership experience also required
  • Acts as a subject matter expert or 'trusted advisor' across the company and may be recognized as an external expert
  • Provides strategy, vision, leadership and direction on clinical development programs or other projects regarding clinical/medical issues
  • Requires in-depth knowledge of the functional area and business needs
  • Possesses industry-leading knowledge
  • Excellent organizational skills
  • Excellent presentation, written and verbal communication skills
  • Ability to synthesize data from multiple sources and modalities and apply advanced analytical thought and judgment
  • Strong leadership, collaboration, and employee development skills
  • Ability to influence others with or without authority at all levels of the organization
  • Proactive, innovative, with excellent problem-solving and decision making skills
  • Ability to work in a cross functional team and matrix environment
  • High degree of planning ability in coordinating the activities of clinical investigations within the limits of clinical research schedules
  • Extensive knowledge of federal regulations regarding clinical studies and the conduct of clinical studies
  • Effective interpersonal skills (ability to be personable and establish good rapport with investigators, study coordinators, and other study personnel)
Responsibilities
  • Drive strategic direction for organizational plans and policies for clinical trials/research and data collection activities
  • Responsible for the implementation of clinical projects
  • Create and foster strong relationships with investigators
  • Collaborates with senior management in the development of strategies, research plans, budgets, and clinical summaries
  • Monitor adherence to protocols
  • Supervise the organization of monitoring procedures and collection of data
  • Synthesize study-related data from multiple sources to drive study/program strategy
  • Monitor clinical trials directly and indirectly through assigned CRAs and CROs
  • Provide necessary input for Investigator Brochures and FDA documents including IND and NDA documents
  • Collaborate on multidisciplinary project teams to deliver development goals
  • Participate in and speak at professional meetings
  • Provide clinical assessment or interpretation of data or literature in the preparation of final study reports, other regulatory documents or scientific publications
  • Anticipate factors that could impact Neurocrine’s strategies and its position in the field and recommend new or innovative solutions
  • Direct the development of protocols and study designs
  • Select, develop and evaluate clinical department personnel to ensure the efficient operation of the function
  • Other duties as assigned
Neurocrine Biosciences

Neurocrine Biosciences

View

Company Stage

IPO

Total Funding

N/A

Headquarters

San Diego, California

Founded

1992

Growth & Insights
Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Simplify Jobs

Simplify's Take

What believers are saying

  • FDA approval of CRENESSITY highlights innovation in rare disease treatment.
  • Partnership with PANTHERx Rare ensures specialized distribution and patient support for CRENESSITY.
  • Growing focus on rare disease treatments supports Neurocrine's strategic direction.

What critics are saying

  • Competition from alternative CAH treatments could impact CRENESSITY's market share.
  • Reliance on PANTHERx Rare for distribution poses a risk if disruptions occur.
  • Potential unidentified side effects of CRENESSITY could lead to regulatory scrutiny.

What makes Neurocrine Biosciences unique

  • CRENESSITY is the first non-steroidal treatment for classic congenital adrenal hyperplasia.
  • Neurocrine's CRENESSITY is a first-in-class CRF1 receptor antagonist for CAH.
  • CRENESSITY allows reduced glucocorticoid doses while maintaining androgen control in CAH patients.

Help us improve and share your feedback! Did you find this helpful?